Why These Two Peptides Together
The "Wolverine Stack" is community shorthand for co-administration of BPC-157 and TB-500 in tissue repair research. The name references the Marvel character's rapid healing ability — it is not a clinical designation.
The research rationale is mechanistic complementarity. BPC-157 and TB-500 do not duplicate each other's effects — they target different stages and pathways of the repair process, which is why researchers study them together.
The stack rationale: TB-500's systemic cell migration creates a circulating pool of repair-competent cells body-wide, while BPC-157's local growth factor upregulation provides targeted signaling at the specific injury site. The two mechanisms converge to produce an additive effect on healing kinetics in preclinical co-administration studies.
Regulatory Status (May 2026)
Both BPC-157 and TB-500 were removed from the FDA's Category 2 restricted list on April 22, 2026. Neither is currently on the Category 1 approved list. The PCAC is scheduled to evaluate both on Day 1 of the July 23–24, 2026 hearing.
Both remain available from US research peptide vendors for research use only. See BPC-157 FDA Status 2026 for the full regulatory timeline.
Vial & Reconstitution Math
- BPC-157 5mg vial + 2.0ml BAC water = 2,500 mcg/ml
- TB-500 5mg vial + 2.0ml BAC water = 2,500 mcg/ml
- Reconstitute each vial separately; inject slowly down the vial wall
- Swirl gently — do not shake either vial
- Label each with name and reconstitution date
- Both stable for 28 days refrigerated with bacteriostatic water
Evo Peptides carries the KLOW 80mg blend — a pre-combined research formulation of BPC-157, TB-500, KPV, and GHK-Cu. Pre-blended vials simplify reconstitution to a single step and ensure consistent ratios across research protocols.
Research Supplies Checklist
For a standard 8-week separate-vial research protocol:
| Item | Qty | Notes |
|---|---|---|
| BPC-157 (5mg vials) | 3–4 | Depends on frequency; 1 vial ≈ 10 days at 500mcg/day |
| TB-500 (5mg vials) | 2–3 | Lower frequency typical in research protocols |
| Bacteriostatic Water (30ml) | 1–2 | One 30ml vial reconstitutes multiple peptide vials |
| Insulin syringes (U-100, 0.5ml) | 100+ | 28–29 gauge, 1/2 inch needle common for SC research |
| Alcohol swabs | 2× syringes | One for vial top, one for administration site |
Co-Administration Notes
Preclinical co-administration studies have generally used simultaneous or near-simultaneous dosing of both compounds. The mechanistic rationale supports this: TB-500's systemic mobilization effects and BPC-157's local signaling work in parallel, not in sequence, making same-day administration the most studied approach.
Some protocols use a "loading phase" approach for TB-500 (higher frequency early in the protocol) with sustained BPC-157 administration throughout. This is based on TB-500's systemic mobilization effect taking time to build a circulating pool of progenitor cells.